TWI907406B - 使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法 - Google Patents

使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法

Info

Publication number
TWI907406B
TWI907406B TW110112266A TW110112266A TWI907406B TW I907406 B TWI907406 B TW I907406B TW 110112266 A TW110112266 A TW 110112266A TW 110112266 A TW110112266 A TW 110112266A TW I907406 B TWI907406 B TW I907406B
Authority
TW
Taiwan
Prior art keywords
fenibrutinib
individual
acceptable salt
pharmaceutically acceptable
baseline
Prior art date
Application number
TW110112266A
Other languages
English (en)
Chinese (zh)
Other versions
TW202203925A (zh
Inventor
希德基 加倫
華同 鄧
奧瑞蓮 維亞科茲
卜丁根 漢斯 克里斯丁 凡
Original Assignee
美商建南德克公司
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商建南德克公司, 瑞士商赫孚孟拉羅股份公司 filed Critical 美商建南德克公司
Publication of TW202203925A publication Critical patent/TW202203925A/zh
Application granted granted Critical
Publication of TWI907406B publication Critical patent/TWI907406B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW110112266A 2020-04-03 2021-04-01 使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法 TWI907406B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063005095P 2020-04-03 2020-04-03
US63/005,095 2020-04-03
US202063051767P 2020-07-14 2020-07-14
US63/051,767 2020-07-14

Publications (2)

Publication Number Publication Date
TW202203925A TW202203925A (zh) 2022-02-01
TWI907406B true TWI907406B (zh) 2025-12-11

Family

ID=75625678

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110112266A TWI907406B (zh) 2020-04-03 2021-04-01 使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法

Country Status (13)

Country Link
US (1) US12605376B2 (cg-RX-API-DMAC7.html)
EP (1) EP4125906A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023520469A (cg-RX-API-DMAC7.html)
KR (1) KR20220163986A (cg-RX-API-DMAC7.html)
CN (1) CN115916205A (cg-RX-API-DMAC7.html)
AU (1) AU2021249129B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019846A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177390A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002699A1 (cg-RX-API-DMAC7.html)
IL (1) IL296990A (cg-RX-API-DMAC7.html)
MX (1) MX2022012310A (cg-RX-API-DMAC7.html)
TW (1) TWI907406B (cg-RX-API-DMAC7.html)
WO (1) WO2021202825A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI899163B (zh) * 2020-02-28 2025-10-01 美商建南德克公司 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
BR112023021235A2 (pt) 2021-05-14 2023-12-12 Loxo Oncology Inc Formas cocristalinas de um inibidor da tirosina quinase de bruton
CN114028393B (zh) * 2021-11-07 2023-07-18 天津医科大学 阿帕替尼在制备治疗多发性硬化症药物的用途
WO2024238524A1 (en) * 2023-05-16 2024-11-21 Genentech, Inc. Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
PL4049660T3 (pl) 2016-02-29 2025-06-09 F. Hoffmann-La Roche Ag Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona
CN107043366B (zh) 2017-04-25 2020-05-26 中国药科大学 4-氨基嘧啶类化合物、其制备方法及医药用途
EP3626239B1 (en) 2017-05-18 2024-07-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ezh2 inhibitor combined with btk inhibitor for treating tumor
US20210113568A1 (en) * 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
JP2022500408A (ja) * 2018-09-12 2022-01-04 デノボ バイオファーマ エルエルシー エンザスタウリンとbtkの阻害剤との組合せおよびその使用
EP3914250A1 (en) 2019-01-22 2021-12-01 F. Hoffmann-La Roche AG Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase
TWI899163B (zh) 2020-02-28 2025-10-01 美商建南德克公司 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 JJ Crawford et al. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development 61(6) J. Med. Chem February 2018 2227−2245
期刊 X Montalban et al. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis 380(25) N Engl J Med 2019 Jun 20 1-12

Also Published As

Publication number Publication date
BR112022019846A2 (pt) 2022-11-22
TW202203925A (zh) 2022-02-01
IL296990A (en) 2022-12-01
AU2021249129B2 (en) 2026-06-04
JP2023520469A (ja) 2023-05-17
CN115916205A (zh) 2023-04-04
US12605376B2 (en) 2026-04-21
KR20220163986A (ko) 2022-12-12
EP4125906A1 (en) 2023-02-08
AU2021249129A1 (en) 2022-10-20
CL2022002699A1 (es) 2023-03-31
WO2021202825A1 (en) 2021-10-07
CA3177390A1 (en) 2021-10-07
US20230149395A1 (en) 2023-05-18
MX2022012310A (es) 2022-10-27

Similar Documents

Publication Publication Date Title
US12605376B2 (en) Methods of treating relapsing multiple sclerosis using an inhibitor of Bruton's tyrosine kinase
TWI794885B (zh) 全身紅斑性狼瘡之治療
US11123329B1 (en) Use of angiotensin II type 2 receptor agonist
JP2026082835A (ja) ブルトン型チロシンキナーゼの阻害剤を使用する一次性進行型多発性硬化症の治療方法
JP2021181501A (ja) 免疫不全疾患を処置するための方法
TW202517276A (zh) 用於治療自體免疫及發炎疾病之rip1激酶抑制劑之調配物及劑量療法
CN109562280B (zh) 复发-缓解型多发性硬化的诊断或预测因子
EP3376869B1 (en) Treatment of autoimmune disease
RU2858695C2 (ru) Способы лечения рецидивирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
WO2025045766A1 (en) Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same
RU2858696C2 (ru) Способы лечения первично-прогрессирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
HK40087403A (en) Methods of treating relapsing multiple sclerosis using an inhibitor of bruton’s tyrosine kinase
EP4630003A1 (en) Methods for treating immune thrombocytopenia in subjects with cognitive impairment by administering rilzabrutinib
EP4634225A1 (en) Anti-ilt7 binding agents for the treatment and prevention of myositis
HK40082153A (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton’s tyrosine kinase
US12600715B2 (en) Soluble guanylate cyclate activators for treating systemic sclerosis
TW202430217A (zh) 用於免疫介導之壞死性肌病變之治療及預防的抗cd19結合劑
WO2025124760A1 (en) Treatment of subpopulation of patients with rheumatoid arthritis
US20140200255A1 (en) Method for administration